Endokrin orbitopathia

Translated title of the contribution: Graves' orbitopathy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Graves' orbitopathy or thyroid associated orbitopathy is the most frequent extrathyreoidal manifestation of Graves' disease with autoimmun mechanism which is still incompletely understood. The epidemiologic data provided evidence that severe, infiltrative orbitopathy is present in 3-5% of patients, and the quality of life is impaired even in individuals with mild form of this disease. The anti-TSH receptor and anti-eye muscle autoantibodies have been proved to be involved into pathomechanism of orbitopathy. The accumulation of glucose-aminoglycan and proinflammatory cytokines in retroorbital fibroblasts are responsible for enlargement of eye muscle and the retroorbital tissues resulting in inflammation of periorbital tissues and proptosis. Management of orbitopathy can be either medical and surgical. The medical therapy relies on the use of high dose systemic glucocorticoids or retroorbital irradiation, either alone or in combination. Recent randomized clinical trials have confirmed that glucocorticoids are more effective in intravenous than oral use. Retroorbital radiotherapy is an effective and safe therapy for orbitopathy and the side effects are avoidable. Somatostatin analogs are not so effective as it has been waited in previous studies. The high dose intravenous immunoglobulins and pentoxifylline therapy are favorable, however, prospective randomized trials have been not yet made. The manifestation of orbitopathy includes both unavoidable (genetic background) and avoidable (smoking, cytokine therapy, iodine exposure, radioiodine therapy) risk factors. The cigarette smoking must be given up for all patients with Graves'disease. Pentoxifylline therapy is advisable for all patients with Graves'diseases, especially for those who have genetic susceptibility to autoimmune disorders and not able to give up cigarette smoking.

Original languageHungarian
Pages (from-to)1011-1017
Number of pages7
JournalOrvosi Hetilap
Volume147
Issue number22
Publication statusPublished - Jun 4 2006

Fingerprint

Graves Disease
Pentoxifylline
Smoking
Glucocorticoids
Implosive Therapy
Cytokines
Thyrotropin Receptors
Muscles
Exophthalmos
Passive Immunization
Intravenous Immunoglobulins
Therapeutics
Genetic Predisposition to Disease
Somatostatin
Iodine
Autoantibodies
Thyroid Gland
Radiotherapy
Randomized Controlled Trials
Fibroblasts

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Balázs, C. (2006). Endokrin orbitopathia. Orvosi Hetilap, 147(22), 1011-1017.

Endokrin orbitopathia. / Balázs, C.

In: Orvosi Hetilap, Vol. 147, No. 22, 04.06.2006, p. 1011-1017.

Research output: Contribution to journalArticle

Balázs, C 2006, 'Endokrin orbitopathia', Orvosi Hetilap, vol. 147, no. 22, pp. 1011-1017.
Balázs C. Endokrin orbitopathia. Orvosi Hetilap. 2006 Jun 4;147(22):1011-1017.
Balázs, C. / Endokrin orbitopathia. In: Orvosi Hetilap. 2006 ; Vol. 147, No. 22. pp. 1011-1017.
@article{72544541f68f4ecda9a8d55c6d62108f,
title = "Endokrin orbitopathia",
abstract = "Graves' orbitopathy or thyroid associated orbitopathy is the most frequent extrathyreoidal manifestation of Graves' disease with autoimmun mechanism which is still incompletely understood. The epidemiologic data provided evidence that severe, infiltrative orbitopathy is present in 3-5{\%} of patients, and the quality of life is impaired even in individuals with mild form of this disease. The anti-TSH receptor and anti-eye muscle autoantibodies have been proved to be involved into pathomechanism of orbitopathy. The accumulation of glucose-aminoglycan and proinflammatory cytokines in retroorbital fibroblasts are responsible for enlargement of eye muscle and the retroorbital tissues resulting in inflammation of periorbital tissues and proptosis. Management of orbitopathy can be either medical and surgical. The medical therapy relies on the use of high dose systemic glucocorticoids or retroorbital irradiation, either alone or in combination. Recent randomized clinical trials have confirmed that glucocorticoids are more effective in intravenous than oral use. Retroorbital radiotherapy is an effective and safe therapy for orbitopathy and the side effects are avoidable. Somatostatin analogs are not so effective as it has been waited in previous studies. The high dose intravenous immunoglobulins and pentoxifylline therapy are favorable, however, prospective randomized trials have been not yet made. The manifestation of orbitopathy includes both unavoidable (genetic background) and avoidable (smoking, cytokine therapy, iodine exposure, radioiodine therapy) risk factors. The cigarette smoking must be given up for all patients with Graves'disease. Pentoxifylline therapy is advisable for all patients with Graves'diseases, especially for those who have genetic susceptibility to autoimmune disorders and not able to give up cigarette smoking.",
keywords = "Autoimmunity, Exogenic factors, Genetic factor, Graves' orbitopathy, Thyroid associated orbitopathy",
author = "C. Bal{\'a}zs",
year = "2006",
month = "6",
day = "4",
language = "Hungarian",
volume = "147",
pages = "1011--1017",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "22",

}

TY - JOUR

T1 - Endokrin orbitopathia

AU - Balázs, C.

PY - 2006/6/4

Y1 - 2006/6/4

N2 - Graves' orbitopathy or thyroid associated orbitopathy is the most frequent extrathyreoidal manifestation of Graves' disease with autoimmun mechanism which is still incompletely understood. The epidemiologic data provided evidence that severe, infiltrative orbitopathy is present in 3-5% of patients, and the quality of life is impaired even in individuals with mild form of this disease. The anti-TSH receptor and anti-eye muscle autoantibodies have been proved to be involved into pathomechanism of orbitopathy. The accumulation of glucose-aminoglycan and proinflammatory cytokines in retroorbital fibroblasts are responsible for enlargement of eye muscle and the retroorbital tissues resulting in inflammation of periorbital tissues and proptosis. Management of orbitopathy can be either medical and surgical. The medical therapy relies on the use of high dose systemic glucocorticoids or retroorbital irradiation, either alone or in combination. Recent randomized clinical trials have confirmed that glucocorticoids are more effective in intravenous than oral use. Retroorbital radiotherapy is an effective and safe therapy for orbitopathy and the side effects are avoidable. Somatostatin analogs are not so effective as it has been waited in previous studies. The high dose intravenous immunoglobulins and pentoxifylline therapy are favorable, however, prospective randomized trials have been not yet made. The manifestation of orbitopathy includes both unavoidable (genetic background) and avoidable (smoking, cytokine therapy, iodine exposure, radioiodine therapy) risk factors. The cigarette smoking must be given up for all patients with Graves'disease. Pentoxifylline therapy is advisable for all patients with Graves'diseases, especially for those who have genetic susceptibility to autoimmune disorders and not able to give up cigarette smoking.

AB - Graves' orbitopathy or thyroid associated orbitopathy is the most frequent extrathyreoidal manifestation of Graves' disease with autoimmun mechanism which is still incompletely understood. The epidemiologic data provided evidence that severe, infiltrative orbitopathy is present in 3-5% of patients, and the quality of life is impaired even in individuals with mild form of this disease. The anti-TSH receptor and anti-eye muscle autoantibodies have been proved to be involved into pathomechanism of orbitopathy. The accumulation of glucose-aminoglycan and proinflammatory cytokines in retroorbital fibroblasts are responsible for enlargement of eye muscle and the retroorbital tissues resulting in inflammation of periorbital tissues and proptosis. Management of orbitopathy can be either medical and surgical. The medical therapy relies on the use of high dose systemic glucocorticoids or retroorbital irradiation, either alone or in combination. Recent randomized clinical trials have confirmed that glucocorticoids are more effective in intravenous than oral use. Retroorbital radiotherapy is an effective and safe therapy for orbitopathy and the side effects are avoidable. Somatostatin analogs are not so effective as it has been waited in previous studies. The high dose intravenous immunoglobulins and pentoxifylline therapy are favorable, however, prospective randomized trials have been not yet made. The manifestation of orbitopathy includes both unavoidable (genetic background) and avoidable (smoking, cytokine therapy, iodine exposure, radioiodine therapy) risk factors. The cigarette smoking must be given up for all patients with Graves'disease. Pentoxifylline therapy is advisable for all patients with Graves'diseases, especially for those who have genetic susceptibility to autoimmune disorders and not able to give up cigarette smoking.

KW - Autoimmunity

KW - Exogenic factors

KW - Genetic factor

KW - Graves' orbitopathy

KW - Thyroid associated orbitopathy

UR - http://www.scopus.com/inward/record.url?scp=33748859904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748859904&partnerID=8YFLogxK

M3 - Article

C2 - 16913090

AN - SCOPUS:33748859904

VL - 147

SP - 1011

EP - 1017

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 22

ER -